Bionsight and Astellas Partner to Develop New Autoimmune Therapy

Bionsight has entered into a global research and development collaboration with Astellas Pharma to discover a potential first-in-class treatment for autoimmune disorders. The partnership will use artificial intelligence (AI) and advanced drug discovery technology to explore new ways of treating diseases linked to the immune system.

Announced on November 20, 2026, the collaboration became effective in November and focuses on developing a potential therapy that targets the innate immune pathway. The companies aim to identify a new treatment approach that works differently from existing autoimmune therapies.

Under the agreement, Bionsight will lead the research programme, including AI-driven molecular design, target validation and lead optimization. Astellas will contribute its scientific expertise, data and development guidance to support the research.

The collaboration will use Bionsight’s proprietary Javelin platform, which combines AI-powered molecular design with chemoproteomics. The technology is designed to study how drug molecules interact with proteins in the human body and identify the specific proteins and binding sites involved.

According to Bionsight, its Javelin platform can analyse how a drug interacts with more than 7,000 proteins at the same time without chemically modifying the drug. This allows researchers to better understand how potential medicines work and identify relevant drug targets at an early stage of development.

The platform could help improve drug discovery by providing a broader view of drug-protein interactions. This information may help researchers identify new biological targets, understand how drug candidates affect the body and improve the selection of promising compounds.

The project has also been selected for the Global Collaboration R&D track of the 2026 SME Technology Innovation Development Program, operated by the Korea Technology and Information Promotion Agency for SMEs (TIPA). The programme supports research and development collaborations involving innovative small and medium-sized companies.

Heejung Yang, CEO of Bionsight, said the partnership represents an important milestone for the company as it works to turn its technology into new drug development programmes. He added that combining Bionsight’s AI and chemoproteomics capabilities with Astellas’ pharmaceutical expertise could help advance innovative treatments for patients with autoimmune disorders.

Founded in 2019, Bionsight is a South Korean biotechnology company focused on developing AI- and chemoproteomics-based technologies for drug discovery and target identification.

The collaboration highlights the growing role of artificial intelligence in pharmaceutical research. By combining advanced computational tools with experimental protein analysis, Bionsight and Astellas aim to identify new treatment opportunities in autoimmune diseases.

The companies now plan to advance their research towards a preclinical drug candidate, marking an early step in the development of a potential new therapy.

You might also like